Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Our mission is to provide innovative, affordable, and easy-to-use diagnostic products to medical professionals around the world.

Our vision is to create a world of improved healthcare and quality of life through the use of our innovative diagnostic products.

Co-Diagnostics was the recipient of the Fast 50 award for one of the 50 most innovative companies in Utah in 2018. The company was also the recipient of the Best New Entrepreneur award from the Gene Haas Foundation in 2018.